(Q31535676)

2 July 2017

1 reference

title

The potential for vigabatrin-induced intramyelinic edema in humans (English)

1 reference

2 July 2017

Cohen JA

1

1 reference

2 July 2017

Fisher RS

2

1 reference

2 July 2017

Brigell MG

3

1 reference

2 July 2017

Peyster RG

4

1 reference

2 July 2017

Sze G

5

1 reference

2 July 2017

publication date

1 February 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

41

1 reference

2 July 2017

issue

2

1 reference

2 July 2017

page(s)

148-157

1 reference

Severe persistent visual field constriction associated with vigabatrin

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Second study supports results of Whitehall study after retirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Effects of vigabatrin on evoked potentials in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Neuropathology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, ?-acetylenic GABA (4-amino-hex-5-ynoic acid) and ?-vinyl GABA (4-amino-hex-5-enoic acid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

A multicentre study of vigabatrin for drug-resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Effects of vigabatrin and of GABA on myelinated rat cerebellar cultures: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Neuropathologic effects and comparative toxicity for dogs of isonicotinic acid hydrazide and its methanosulfonate derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Vigabatrin: no microvacuoles in a human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Effects of vigabatrin on evoked potentials in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

MRI findings in epileptic patients on vigabatrin for more than 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

Cognitive effects of vigabatrin: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB00134.X

10.1111/J.1528-1157.2000.TB00134.X

21 January 2018

Identifiers

DOI

1 reference

2 July 2017

1 reference